



9381 Judicial Drive, Ste.180
San Diego, CA 92121
Tel: 858.202.4900
Fax: 858.450-6849

NVENTA APPOINTS GORDON H. BUSENBARK TO BOARD OF DIRECTORS

-- Busenbark Provides Additional Global Corporate Finance, Management and Manufacturing Experience --

FOR IMMEDIATE RELEASE

May 28, 2008

San Diego, California USA - Nventa Biopharmaceuticals Corporation (TSX:NVN) announced today the appointment of Gordon H. Busenbark to the company's board of directors. Mr. Busenbark currently serves as the chief financial officer of Xytis Pharmaceuticals, a privately held development-stage specialty pharmaceuticals company focused on diseases of the central nervous system.

"With his extensive experience in the pharmaceutical, biotech and vaccine industries, Gordon is a valuable addition to Nventa's board," commented Gregory M. McKee, president and chief executive officer at Nventa. "His 28 years of industry experience include overseeing billion dollar businesses in both the U.S. and Europe. We believe this key global experience, coupled with his proven track record in corporate finance and manufacturing, will serve Nventa well as we continue to advance our lead product candidate through development and toward commercialization."

Prior to joining Xytis in 2007, Mr. Busenbark was the chief financial officer of Encysive Pharmaceuticals, a publicly traded specialty pharmaceuticals company focused on vascular disease. In this role, he was responsible for securing external financing, all aspects of Security and Exchange Commission (SEC) reporting, Sarbanes-Oxley compliance, budgeting, forecasting, strategic planning and investor relations activities. From 1981 through 2004, Mr. Busenbark held various leadership positions with Baxter Healthcare Corporation, including president of Baxter BioScience's plasma therapeutics business in Vienna, Austria. Mr. Busenbark began his career as a senior financial analyst at Burroughs Corporation. He received a bachelor of science degree in accounting and an MBA from the University of Utah in Salt Lake City.

"Nventa's HspE7 therapeutic vaccine for the treatment of HPV-related diseases places the company at the center of a very exciting segment of the drug development industry and I am pleased to be connected to the company's important work," said Mr. Busenbark. "I look forward to collaborating with the other members of the Nventa board and leveraging my industry experience to help the company achieve success."

About Nventa Biopharmaceuticals Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The Company is publicly traded on the Toronto Stock Exchange under the symbol NVN.

For more information about Nventa Biopharmaceuticals Corporation, please visit the Company's website located at www.nventacorp.com.

Contact:

Donna Slade
Director, Investor Relations
9381 Judicial Drive, Suite 180
San Diego, CA USA 92121
Dir: 858.202.4945
dslade@nventacorp.com

Tim Brons (media)
Vida Communication
415.675.7402
tbrons@vidacommunication.com

Michael Moore
The Equicom Group
416.815.0700, ext. 241
mmoore@equicomgroup.com